Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time.These characteristics allow for the improvement and extension of clinical screening programmes, globally.

Zilico’s product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology which has applicability across a wide range of neoplastic conditions. The first application is focused on the early and accurate detection of Cervical Cancer.

Status current

Associated Fund Harwell Capital

Sector Medical / Biotechnology


More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now